The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing
Open accessAbstract
Oncolytic herpes simplex virus type 1 (HSV-1) vectors are promising therapeutic agents for cancer. Their efficacy depends on the extent of both intratumoral viral replication and induction of a host antitumor immune response. To enhance these properties while employing ample safeguards, two conditionally replicating HSV-1 vectors, termed G47Δ and R47Δ, have been constructed by deleting the α47 gene and the promoter region of US11 from γ34.5-deficient HSV-1 vectors, G207 and R3616, respectively. Because the α47 gene product is responsible for inhibiting the transporter associated with antigen presentation (TAP), its absence led to increased MHC class I expression in infected human cells. Moreover, some G47Δ-infected human melanoma cells exhibited enhanced stimulation of matched antitumor T cell activity. The deletion also places the late US11 gene under control of the immediate-early α47 promoter, which suppresses the reduced growth properties of γ34.5-deficient mutants. G47Δ and R47Δ showed enhanced viral growth in a variety of cell lines, leading to higher virus yields and enhanced cytopathic effect in tumor cells. G47Δ was significantly more efficacious in vivo than its parent G207 at inhibiting tumor growth in both immune-competent and immune-deficient animal models. Yet, when inoculated into the brains of HSV-1-sensitive A/J mice at 2 × 10 6 plaque forming units, G47Δ was as safe as G207. These results suggest that G47Δ may have enhanced antitumor activity in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Self-citationAttenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas
Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., & Martuza, R. L. (1995) · Nature Medicine · doi:10.1038/nm0995-938 · Cited by 822
Self-citationHerpes simplex virus turns off the TAP to evade host immunity
Hill, A., Jugovic, P., York, L., Russ, G., Bennink, J., Yewdell, J., Ploegh, H., & Johnson, D. (1995) · Nature · doi:10.1038/375411a0 · Cited by 803
Herpes simplex virus turns off the TAP to evade host immunity
(1995) · Trends in Genetics · doi:10.1016/0168-9525(95)90181-7 · Cited by 736
Chou, J., Kern, E. R., Whitley, R. J., & Roizman, B. (1990) · Science · doi:10.1126/science.2173860 · Cited by 711
A viral inhibitor of peptide transporters for antigen presentation
Früh, K., Ahn, K., Djaballah, H., Sempé, P., van Endert, P. M., Tampé, R., Peterson, P. A., & Yang, Y. (1995) · Nature · doi:10.1038/375415a0 · Cited by 602
A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes
York, I. A., Roop, C., Andrews, D. W., Riddell, S. R., Graham, F. L., & Johnson, D. C. (1994) · Cell · doi:10.1016/0092-8674(94)90215-1 · Cited by 559
Chou, J., & Roizman, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3266 · Cited by 393
Goldstein, D. J., & Weller, S. K. (1988) · Journal of Virology · doi:10.1128/jvi.62.1.196-205.1988 · Cited by 392
Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47.
Ahn, K., Meyer, T. H., Uebel, S., Sempé, P., Djaballah, H., Yang, Y., Peterson, P. A., Früh, K., & Tampé, R. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00689.x · Cited by 358
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Liu, B. L., Robinson, M., Han, Z.-Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301885 · Cited by 803
Oncolytic virus therapy: A new era of cancer treatment at dawn
Fukuhara, H., Ino, Y., & Todo, T. (2016) · Cancer Science · doi:10.1111/cas.13027 · Cited by 774
Self-citationOncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Liu, Y., Zhou, F., Ali, H., Lathia, J. D., & Chen, P. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01226-x · Cited by 336
Metadata
- Authors
- Todo, T., Martuza, R. L., Rabkin, S. D., & Johnson, P. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2001-05-15
- Volume
- 98
- Issue
- 11
- Pages
- 6396-6401
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2165652424
- Cited by
- 465
- References
- 31
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. https://app.cochat.ai/papers/10.1073/pnas.101136398
- The paper
- Todo, T., Martuza, R. L., Rabkin, S. D., & Johnson, P. A. (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.101136398
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.